Use of Psychotropic Medication in Victims of Sudden Cardiac Death with Nonischemic Heart Disease.
Medicolegal autopsy
Nonischemic heart disease
Psychotropic medication
Sudden cardiac death
Journal
Cardiology
ISSN: 1421-9751
Titre abrégé: Cardiology
Pays: Switzerland
ID NLM: 1266406
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
12
2022
accepted:
26
01
2023
medline:
2
6
2023
pubmed:
9
2
2023
entrez:
8
2
2023
Statut:
ppublish
Résumé
Nonischemic heart disease (NIHD) is the underlying pathology in about 20% of sudden cardiac deaths (SCDs). Psychotropic medication has been reported as a risk factor for SCD among patients with coronary artery disease, but similar information concerning NIHD is scarce. We evaluated the use of psychotropic medication in victims of SCD due to NIHD and compared it to the general medication use in Finland. Study population was derived from the Finnish Genetic Study of Arrhythmic Events (Fingesture) (n = 5,869, mean age: 65 ± 12, 79% males; 1,404 victims of SCD due to NIHD, mean age: 57 ± 13, 77% males). All deaths occurred in Northern Finland during 1998-2017. All victims underwent a medicolegal autopsy. Data on use of medication were defined using postmortem toxicology results and patient records. Subjects with neither toxicological analysis nor information of medication use available were excluded. Information on general medication use was derived from Finnish Statistics on Medicines 2018 and presented as defined daily dose/1,000 inhabitants/day. Psychotropic medication was used by 579 (41%) subjects with NIHD, whereas in the general population, only 12% were estimated to use psychotropics. The results were similar in subgroups of psychotropic medication: 27% versus 2.3% for benzodiazepines, 19% versus 7.5% for antidepressants, and 18% versus 2.2% for antipsychotics. Use of psychotropic medication is common in victims of SCD due to NIHD compared to the general population.
Sections du résumé
BACKGROUND
Nonischemic heart disease (NIHD) is the underlying pathology in about 20% of sudden cardiac deaths (SCDs). Psychotropic medication has been reported as a risk factor for SCD among patients with coronary artery disease, but similar information concerning NIHD is scarce.
OBJECTIVES
We evaluated the use of psychotropic medication in victims of SCD due to NIHD and compared it to the general medication use in Finland.
METHOD
Study population was derived from the Finnish Genetic Study of Arrhythmic Events (Fingesture) (n = 5,869, mean age: 65 ± 12, 79% males; 1,404 victims of SCD due to NIHD, mean age: 57 ± 13, 77% males). All deaths occurred in Northern Finland during 1998-2017. All victims underwent a medicolegal autopsy. Data on use of medication were defined using postmortem toxicology results and patient records. Subjects with neither toxicological analysis nor information of medication use available were excluded. Information on general medication use was derived from Finnish Statistics on Medicines 2018 and presented as defined daily dose/1,000 inhabitants/day.
RESULTS
Psychotropic medication was used by 579 (41%) subjects with NIHD, whereas in the general population, only 12% were estimated to use psychotropics. The results were similar in subgroups of psychotropic medication: 27% versus 2.3% for benzodiazepines, 19% versus 7.5% for antidepressants, and 18% versus 2.2% for antipsychotics.
CONCLUSIONS
Use of psychotropic medication is common in victims of SCD due to NIHD compared to the general population.
Identifiants
pubmed: 36754034
pii: 000529501
doi: 10.1159/000529501
doi:
Substances chimiques
Psychotropic Drugs
0
Types de publication
News
Langues
eng
Sous-ensembles de citation
IM
Pagination
134-137Informations de copyright
© 2023 S. Karger AG, Basel.